Phase Ib Trial of Niraparib and Copanlisib for Recurrent Gynecological Cancers
A phase Ib trial is underway to evaluate the safety and dosing of niraparib and copanlisib in recurrent gynecological cancers.
Therapeutic Area
Therapeutic area intelligence for PARP Inhibitor and PI3K Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.